Summary
University of Oxford (UO) is a research and educational university that offers student training, academic research and graduation programs. The university offers graduation courses under humanities, mathematical, physical and life sciences; medical sciences, and continuity education departments. Its mathematical, physical and life sciences courses comprise doctoral training programs, chemistry, computer science, earth sciences, engineering science, materials, mathematics, physics, plant sciences, statistics and zoology, among others. The university offers various undergraduate courses, graduate courses, lifelong learning and online and distance courses through its colleges. UO is headquartered in Oxford, the UK.
University of Oxford - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
University of Oxford, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
University of Oxford, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
University of Oxford, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
University of Oxford, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
University of Oxford, Medical Devices Deals, 2010 to YTD 2016 10
University of Oxford, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
University of Oxford, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Genomics Raises USD16 Million in Venture Financing 15
Adaptimmune Raises USD104 Million in Series A Venture Financing 17
Oxitec Raises USD10.2 Million in Venture Financing 19
Chronos Therapeutics Raises US$13 Million In Venture Financing 21
Partnerships 23
MDNA Life Sciences Enters into Agreement with University of Oxford 23
Idogen Enters into Agreement with University of Oxford 24
Sound Pharma to Partner with University of Oxford 25
Summit Therapeutics Enters into Agreement with University of Oxford 26
Genomics Enters into Agreement with Oxford University and Oxford University Hospitals NHS 27
Wave Life Sciences Enters into Research Agreement with University of Oxford 28
Cell Therapy Catapult, Plasticell and University of Oxford Enter into Agreement 29
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 30
Chan Soon-Shiong Institute Forms Joint Venture with University of Oxford 32
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 33
MRC Technology Enters Into Co-Development Agreement With Oxford University 34
Creeyan Labs Enters Into Co-Development Agreement With Oxford University 35
iQur Enters Into Co-Development Agreement With Edward Jenner Institute For Malaria Vaccine 36
Emerald Biostructures Enters Into Co-Marketing Agreement With University of Oxford For PiMS Technology 37
Population Genetics Technologies Enters Into Co-Development Agreement With University of Oxford 38
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 39
UCB Enters Into Co-Development Agreement With Oxford University 40
ValiRx Enters Into Co-Development Agreement With Oxford University 41
Cancer Research UK Enters Into Joint Venture Agreement With University Of Oxford And Oxford Radcliffe 42
Sanofi-Aventis And Oxford University Enter Into Research Agreement With INDOX 43
Kennedy Institute of Rheumatology Trust Enters Into Collaboration Agreement With University of Oxford 45
Isconova Enters Into Agreement With Jenner Institute To Develop Vaccines 46
Oxford Nanopore Technologies Enters Into Collaboration With University Of Oxford 47
Licensing Agreements 48
Vaccitech Enters into Licensing Agreement with University of Oxford 48
Rogne Bioscience Enters Into Licensing Agreement with Isis Innovation 49
ExpreS2ion Biotech Enters Into Licensing Agreement With University of Oxford For ExpreS2 50
Oxford Nutrascience Enters Into Licensing Agreement With Isis Innovation 51
Imaxio Enters Into Licensing Agreement With Isis Innovation 52
Equity Offering 53
Perspectum Diagnostics Raises USD5 Million in Financing 53
University of Oxford - Key Competitors 54
Key Employees 55
Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List of Tables
University of Oxford, Pharmaceuticals & Healthcare, Key Facts 1
University of Oxford, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
University of Oxford, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
University of Oxford, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
University of Oxford, Deals By Therapy Area, 2010 to YTD 2016 9
University of Oxford, Medical Devices Deals, 2010 to YTD 2016 10
University of Oxford, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Genomics Raises USD16 Million in Venture Financing 15
Adaptimmune Raises USD104 Million in Series A Venture Financing 17
Oxitec Raises USD10.2 Million in Venture Financing 19
Chronos Therapeutics Raises US$13 Million In Venture Financing 21
MDNA Life Sciences Enters into Agreement with University of Oxford 23
Idogen Enters into Agreement with University of Oxford 24
Sound Pharma to Partner with University of Oxford 25
Summit Therapeutics Enters into Agreement with University of Oxford 26
Genomics Enters into Agreement with Oxford University and Oxford University Hospitals NHS 27
Wave Life Sciences Enters into Research Agreement with University of Oxford 28
Cell Therapy Catapult, Plasticell and University of Oxford Enter into Agreement 29
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 30
Chan Soon-Shiong Institute Forms Joint Venture with University of Oxford 32
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 33
MRC Technology Enters Into Co-Development Agreement With Oxford University 34
Creeyan Labs Enters Into Co-Development Agreement With Oxford University 35
iQur Enters Into Co-Development Agreement With Edward Jenner Institute For Malaria Vaccine 36
Emerald Biostructures Enters Into Co-Marketing Agreement With University of Oxford For PiMS Technology 37
Population Genetics Technologies Enters Into Co-Development Agreement With University of Oxford 38
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 39
UCB Enters Into Co-Development Agreement With Oxford University 40
ValiRx Enters Into Co-Development Agreement With Oxford University 41
Cancer Research UK Enters Into Joint Venture Agreement With University Of Oxford And Oxford Radcliffe 42
Sanofi-Aventis And Oxford University Enter Into Research Agreement With INDOX 43
Kennedy Institute of Rheumatology Trust Enters Into Collaboration Agreement With University of Oxford 45
Isconova Enters Into Agreement With Jenner Institute To Develop Vaccines 46
Oxford Nanopore Technologies Enters Into Collaboration With University Of Oxford 47
Vaccitech Enters into Licensing Agreement with University of Oxford 48
Rogne Bioscience Enters Into Licensing Agreement with Isis Innovation 49
ExpreS2ion Biotech Enters Into Licensing Agreement With University of Oxford For ExpreS2 50
Oxford Nutrascience Enters Into Licensing Agreement With Isis Innovation 51
Imaxio Enters Into Licensing Agreement With Isis Innovation 52
Perspectum Diagnostics Raises USD5 Million in Financing 53
University of Oxford, Key Competitors 54
University of Oxford, Key Employees 55
University of Oxford, Subsidiaries 56
List of Figures
University of Oxford, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
University of Oxford, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
University of Oxford, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
University of Oxford, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
University of Oxford, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
University of Oxford, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
University of Oxford, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
University of Oxford, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
University of Oxford, Medical Devices Deals, 2010 to YTD 2016 10
